The primary results of SOFT and TEXT, which were published in the New England Journal of Medicine in 2014, were supported by a 5-year analysis presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). The most recent results presented at the 2021 SABCS, with patients having been followed-up for an average of 12.5 years since starting treatment, show a persistent long-term reduction of risk of distant recurrence when OFS is added to tamoxifen or exemestane, with the greatest reduction found in combination with exemestane. The updated results also demonstrate a reduction in death with both combinations, although the reduction was higher with exemestane.